| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
200,590,000 |
| Market
Cap: |
7.60(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.13 - $60.6 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. Co.'s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which Co. refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target main nodes in the RAS pathway or associated pathways, which Co. refers to as RAS Companion Inhibitors. Co.'s RAS Companion Inhibitors (example, SHP2, mTORC1 and SOS1 inhibitors) are designed primarily for combination treatment strategies involving one or more therapeutic agents, which may include its RAS(ON) Inhibitors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,304,347 |
1,304,347 |
| Total Buy Value |
$0 |
$0 |
$59,999,962 |
$59,999,962 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
29,428 |
55,287 |
432,277 |
815,080 |
| Total Sell Value |
$1,171,699 |
$2,184,081 |
$20,819,368 |
$33,440,035 |
| Total People Sold |
6 |
6 |
8 |
8 |
| Total Sell Transactions |
7 |
14 |
46 |
98 |
| End Date |
2025-04-06 |
2025-01-03 |
2024-07-05 |
2023-07-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Goldsmith Mark A |
See Remarks |
• • – |
2025-06-30 |
4 |
OE |
$0.54 |
$19,980 |
D/D |
37,000 |
465,720 |
|
- |
|
| Kim Lorence H. |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
73,090 |
|
- |
|
| Anderson Elizabeth M |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
23,215 |
|
- |
|
| Patel Sushil |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
23,090 |
|
- |
|
| Clyburn Frank |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,806 |
9,738 |
|
- |
|
| Horning Sandra |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
96,574 |
|
- |
|
| Borellini Flavia |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
25,024 |
|
- |
|
| Borisy Alexis |
|
• • – |
2025-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
2,338,884 |
|
- |
|
| Cislini Jeff |
General Counsel |
• • – |
2025-06-20 |
4 |
AS |
$39.61 |
$75,736 |
D/D |
(1,912) |
54,093 |
|
-7% |
|
| Wei Lin |
Chief Medical Officer |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$86,551 |
D/D |
(2,173) |
90,499 |
|
-7% |
|
| Kelsey Stephen Michael |
See Remarks |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$170,831 |
D/D |
(4,289) |
289,414 |
|
-7% |
|
| Goldsmith Mark A |
See Remarks |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$537,546 |
D/D |
(13,496) |
428,720 |
|
-7% |
|
| Horn Margaret A |
Chief Operating Officer |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$139,803 |
D/D |
(3,510) |
150,675 |
|
-7% |
|
| Anders Jack |
Chief Financial Officer |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$86,431 |
D/D |
(2,170) |
113,314 |
|
-7% |
|
| Cislini Jeff |
General Counsel |
• • – |
2025-06-16 |
4 |
AS |
$39.83 |
$74,801 |
D/D |
(1,878) |
56,005 |
|
-7% |
|
| Cislini Jeff |
General Counsel |
• • – |
2025-03-20 |
4 |
AS |
$38.71 |
$79,008 |
D/D |
(2,041) |
57,723 |
|
-4% |
|
| Cislini Jeff |
General Counsel |
• • – |
2025-03-17 |
4 |
AS |
$39.04 |
$56,921 |
D/D |
(1,458) |
59,764 |
|
-6% |
|
| Horn Margaret A |
Chief Operating Officer |
• • – |
2025-03-17 |
4 |
AS |
$39.04 |
$119,385 |
D/D |
(3,058) |
153,533 |
|
-6% |
|
| Anders Jack |
Chief Financial Officer |
• • – |
2025-03-17 |
4 |
AS |
$39.04 |
$72,771 |
D/D |
(1,864) |
115,006 |
|
-6% |
|
| Goldsmith Mark A |
See Remarks |
• • – |
2025-03-17 |
4 |
AS |
$39.04 |
$458,255 |
D/D |
(11,738) |
441,564 |
|
-6% |
|
| Wang Xiaolin |
See Remarks |
• • – |
2025-03-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,718 |
102,321 |
|
- |
|
| Kelsey Stephen Michael |
See Remarks |
• • – |
2025-03-17 |
4 |
AS |
$39.04 |
$128,599 |
D/D |
(3,294) |
293,051 |
|
-6% |
|
| Cislini Jeff |
General Counsel |
• • – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
61,222 |
|
- |
|
| Goldsmith Mark A |
See Remarks |
• • – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
97,400 |
453,302 |
|
- |
|
| Horn Margaret A |
Chief Operating Officer |
• • – |
2025-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
28,600 |
156,591 |
|
- |
|
447 Records found
|
|
Page 1 of 18 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.68 (1.83%) 
